Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Natural health product Libidfit may pose health risks

Jan 26, 2006 | Health Canada

Health Canada is warning consumers not to use the natural health product Libidfit because it has been found to contain an undeclared ingredient that could lead to serious health risks, especially for patients with existing medical conditions such as heart problems.

Libidfit is promoted for sexual enhancement and erectile dysfunction, but contains an undeclared amount of a pharmaceutical ingredient similar to sildenafil, which could pose a health risk when used without medical supervision, especially in those individuals who may be taking heart medications or who have heart problems or are at risk for strokes. Sildenafil has also been associated with serious side-effects including sudden vision loss, penile tissue damage and urinary tract infection.

This product is not authorized for sale in Canada, but it may be available to Canadian consumers through personal importation, the Internet or other venues. Canadians who may have purchased Libidfit over the Internet or while travelling abroad are warned not to use it, and to consult with a health care professional if they have concerns about their health due to this product.

Libidfit is manufactured by Libidfit AG, and has been found for sale in Denmark and on the Internet. As a result, the Danish Medicines Agency issued a public warning about the risks associated with Libidfit.

Health Canada also advises Canadians to contact the Health Products and Food Branch Inspectorate at 1-800-267-9675 if they find Libidfit products in Canada. Health Canada has notified the Canada Border Services Agency to detain any shipment of Libidfit at the border.

To date, no adverse reactions from the use of this product has been reported in Canada. To report a suspected adverse reaction, please contact the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) of Health Canada by one of the following methods:
Telephone: 866-234-2345
Facsimile: 866-678-6789.

Libidfit is promoted for sexual enhancement and erectile dysfunction, but contains an undeclared amount of a pharmaceutical ingredient similar to sildenafil, which could pose a health risk when used without medical supervision, especially in those individuals who may be taking heart medications or who have heart problems or are at risk for strokes. Sildenafil has also been associated with serious side-effects including sudden vision loss, penile tissue damage and urinary tract infection.

This product is not authorized for sale in Canada, but it may be available to Canadian consumers through personal importation, the Internet or other venues. Canadians who may have purchased Libidfit over the Internet or while travelling abroad are warned not to use it, and to consult with a health care professional if they have concerns about their health due to this product.

Libidfit is manufactured by Libidfit AG, and has been found for sale in Denmark and on the Internet. As a result, the Danish Medicines Agency issued a public warning about the risks associated with Libidfit.

Health Canada also advises Canadians to contact the Health Products and Food Branch Inspectorate at 1-800-267-9675 if they find Libidfit products in Canada. Health Canada has notified the Canada Border Services Agency to detain any shipment of Libidfit at the border.

To date, no adverse reactions from the use of this product has been reported in Canada. To report a suspected adverse reaction, please contact the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) of Health Canada by one of the following methods:

Telephone: 866-234-2345
Facsimile: 866-678-6789


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo